Simplex Trading’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.97M | Sell |
36,200
-40,100
| -53% | -$2.11M | ﹤0.01% | 2054 |
|
|
2026
Q1 | $3.63M | Sell |
76,300
-65,000
| -46% | -$3.43M | ﹤0.01% | 1348 |
|
|
2025
Q4 | $7.41M | Sell |
141,300
-12,600
| -8% | -$755K | ﹤0.01% | 1035 |
|
|
2025
Q3 | $9.97M | Buy |
153,900
+55,600
| +57% | +$3.19M | 0.01% | 974 |
|
|
2025
Q2 | $4.78M | Buy |
98,300
+27,000
| +38% | +$1.04M | ﹤0.01% | 1381 |
|
|
2025
Q1 | $2.43M | Sell |
71,300
-55,400
| -44% | -$2.35M | ﹤0.01% | 1866 |
|
|
2024
Q4 | $4.99M | Buy |
126,700
+15,900
| +14% | +$751K | ﹤0.01% | 1482 |
|
|
2024
Q3 | $5.21M | Sell |
110,800
-39,200
| -26% | -$1.99M | ﹤0.01% | 1461 |
|
|
2024
Q2 | $8.1M | Sell |
150,000
-78,300
| -34% | -$4.53M | 0.01% | 1147 |
|
|
2024
Q1 | $15.6M | Buy |
228,300
+44,100
| +24% | +$3.16M | 0.01% | 854 |
|
|
2023
Q4 | $11.5M | Buy |
184,200
+53,200
| +41% | +$2.94M | 0.01% | 999 |
|
|
2023
Q3 | $5.95M | Buy |
131,000
+43,600
| +50% | +$2.25M | ﹤0.01% | 1225 |
|
|
2023
Q2 | $4.91M | Buy |
87,400
+13,900
| +19% | +$789K | ﹤0.01% | 1331 |
|
|
2023
Q1 | $3.32M | Sell |
73,500
-2,300
| -3% | -$112K | ﹤0.01% | 1551 |
|
|
2022
Q4 | $3.08M | Buy |
75,800
+47,800
| +171% | +$2.54M | ﹤0.01% | 1545 |
|
|
2022
Q3 | $1.83M | Sell |
28,000
-30,500
| -52% | -$2.21M | ﹤0.01% | 2043 |
|
|
2022
Q2 | $3.56M | Sell |
58,500
-15,000
| -20% | -$882K | ﹤0.01% | 1369 |
|
|
2022
Q1 | $4.61M | Sell |
73,500
-700
| -0.9% | -$44K | ﹤0.01% | 1309 |
|
|
2021
Q4 | $5.62M | Sell |
74,200
-1,200
| -2% | -$105K | 0.01% | 1136 |
|
|
2021
Q3 | $11.8M | Buy |
75,400
+2,200
| +3% | +$276K | 0.01% | 657 |
|
|
2021
Q2 | $11.8M | Buy |
73,200
+72,905
| +24,714% | +$8.87M | 0.01% | 644 |
|
|
2021
Q1 | $3.59M | Sell |
295
-118
| -29% | -$17.8K | 0.01% | 1088 |
|
|
2020
Q4 | $6.32M | Buy |
413
+59
| +17% | +$6.97K | 0.01% | 827 |
|
|
2020
Q3 | $2.96M | Sell |
354
-135
| -28% | -$12K | ﹤0.01% | 1211 |
|
|
2020
Q2 | $3.59M | Buy |
489
+41
| +9% | +$2.4K | 0.01% | 1071 |
|
|
2020
Q1 | $1.9M | Buy |
448
+66
| +17% | +$3.41K | ﹤0.01% | 1321 |
|
|
2019
Q4 | $2.33M | Buy |
382
+111
| +41% | +$6.06K | 0.01% | 1352 |
|
|
2019
Q3 | $1.11M | Sell |
271
-7
| -3% | -$334 | ﹤0.01% | 1832 |
|
|
2019
Q2 | $1.31M | Buy |
278
+105
| +61% | +$4.2K | ﹤0.01% | 1662 |
|
|
2019
Q1 | $617K | Buy |
173
+107
| +162% | +$3.7K | ﹤0.01% | 2440 |
|
|
2018
Q4 | $188K | Buy |
66
+13
| +25% | +$452 | ﹤0.01% | 3216 |
|
|
2018
Q3 | $235K | Sell |
53
-123
| -70% | -$6.44K | ﹤0.01% | 3466 |
|
|
2018
Q2 | $1.03M | Sell |
176
-258
| -59% | -$14.7K | ﹤0.01% | 1759 |
|
|
2018
Q1 | $223K | Buy |
434
+404
| +1,347% | +$16.7K | 0.01% | 1168 |
|
|
2017
Q4 | $14K | Sell |
30
-23
| -43% | -$437 | ﹤0.01% | 3623 |
|
|
2017
Q3 | $27K | Buy |
+53
| New | +$961 | ﹤0.01% | 2872 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Simplex Trading's CRSP Position: Q2 2026 in Review
Simplex Trading sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 1,407 shares — an estimated $74.2K sold.
Simplex Trading first reported a position in CRSP in Q3 2017 and held it in 20 quarters. The position peaked at $3.27M in Q4 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Simplex Trading reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
- Simplex Trading sold 1,407 CRISPR Therapeutics shares in Q2 2026, an estimated $74.2K.
- Simplex Trading first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 20 quarters.
- Simplex Trading's CRISPR Therapeutics position peaked at $3.27M in Q4 2024.
- 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.